Please use this identifier to cite or link to this item:
|Title:||The Therapeutic Potential of Anti-HER2 2Rs15d Nanobody Labeled with 225Ac – an In Vitro and In Vivo Evaluation|
|Authors:||PRUSZYNSKI MAREK; D'HUYVETTER MATTHIAS; RODAK MAGDALENA; DEKEMPENEER YANA; CEDROWSKA EDYTA; LAHOUTTE TONY; BRUCHERTSEIFER FRANK; MORGENSTERN ALFRED|
|Citation:||JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES vol. 50 no. 1 p. S7|
|Type:||Articles in periodicals and books|
|Abstract:||Human Epidermal Growth Factor Receptor type 2 (HER2) is overexpressed in numerous carcinomas and is often associated with a higher recurrence rate and a shorter time to relapse. Nanobodies (Nbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and targeted radionuclide therapy (TRT). HER2-targeting nanobodies are very attractive vectors for TRT, especially when labeled with α-particle emitters, which provide highly lethal and localized radiation to targeted cells with minimal exposure to surrounding healthy tissues. The aim of this study was to evaluate the therapeutic potential of the anti-HER2 Nb 2Rs15d labeled with 225Ac.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.